STAB

Statera Biopharma, Inc. Common Stock

STAB

Market cap $4.98M

Delisted

STAB was delisted on the 11th of January, 2023.

About: Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.

Employees: 16

Healthcare Drug Manufacturers - General

Financial journalist opinion

Neutral

Business Wire

6 months ago

Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health Systems, Inc., (Nasdaq: TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC: STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement estab.

See News Rankings

Charts implemented using Lightweight Charts™

Statera Biopharma, Inc. Common Stock STAB Market cap $4.98M

Financial journalist opinion

Statera Biopharma, Inc. Common Stock

STAB

Market cap $4.98M